GORTEC
GORTEC is a French academic clinical research cooperative group that designs and coordinates multi-center Phase III clinical trials in head and neck oncology across France, Belgium, and Spain, funded by membership dues, grants, and pharmaceutical sponsorships.
- Company typePrivate
- Founded1994
- HeadquartersTours, France
- Headcount11–50
- GTM typeB2B
- OfferingServices
What GORTEC does
GORTEC (Groupe d'Oncologie Radiothérapie Tête Et Cou) is a French academic clinical research cooperative group founded in 1994 and headquartered in Tours, France. It coordinates multi-center clinical and biological studies — including Phase III trials — in head and neck oncology and radiotherapy, operating under a French association loi 1901 / groupement d'intérêt scientifique structure governed by its member researchers and academic medical centers rather than external shareholders. The organization manages a portfolio of 15+ active trials (ILLUMINE, IDEAL, TATIANA, AdCC, XXL, NIVOPOST-OP, StereoPostOp, SANTAL, Pembrorad, OMET, SALTORL, TPFmORL, REWRITe, SIMPA01, REACH) with regulatory footprint in France, Belgium, and Spain, and publishes the Journal du GORTEC and trial-specific newsletters as its primary member-facing communications. GORTEC's recent scientific milestone was the ASCO 2025 plenary presentation of NIVOPOST-OP results demonstrating 63% disease-free survival at 3 years with post-operative nivolumab, an +11% absolute cure-rate improvement over control.
GORTEC's revenue mechanics are non-commercial: it does not sell products or services at list price and is funded through a mix of member contributions, public and institutional research grants, and pharmaceutical industrial-partner co-sponsorship. Its named industrial sponsors include AstraZeneca, Bicara Therapeutics, Leo Pharma, Merck Group, Merck MSD, Nanobiotix, and Summit Therapeutics. Distribution and outreach occur through medical congresses (ASCO, ESTRO), peer-reviewed publications, internal newsletters, the LinkedIn professional channel, and joint annual meetings with Intergroupe ORL (IGORL). GORTEC's primary "customer" base is oncology professionals — radiation oncologists, medical oncologists, and head and neck surgeons — across European academic medical centers.
Its technology stack is conventional for an academic cooperative group: trial-protocol design, multi-center coordination, translational research workflows, and a literature-watch (veille bibliographique) service. No proprietary software products, APIs, AI/ML systems, or commercial platform components are disclosed in the source data.
GORTEC firmographics
Firmographics- Name
- GORTEC
- Legal name
- GORTEC - Groupe d'Oncologie Radiothérapie Tête Et Cou
- Website
- https://gortec.net
- Company type
- Private
- Founded year
- 1994
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- GORTEC is a French academic clinical research cooperative group that designs and coordinates multi-center Phase III clinical trials in head and neck oncology across France, Belgium, and Spain, funded by membership dues, grants, and pharmaceutical sponsorships.
- Ownership category
- akta.pro rank
GORTEC industry classification
Industry- Product category
- Oncology Clinical Research Services
- NAICS
- Other Scientific and Technical Consulting Services (54169)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Medical Oncology (HLAKAFAB)
- akta.pro secondary industries
- Clinical Research & Trial Central Laboratories (HLAFAMAL), Clinical Trial Site Operations & Study Coordination (HLAGACAE)
Keywords
Where GORTEC is headquartered
LocationHeadquarters
- HQ city
- Tours
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
GORTEC business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Marketing channels4 records
GORTEC product offering
Product offeringCore offering
GORTEC is a French academic cooperative group that coordinates and manages multi-center clinical trials and biological studies in head and neck oncology and radiation oncology. The organization designs, initiates, and oversees Phase III and translational research studies, collaborating with academic medical centers and pharmaceutical industrial partners across France, Belgium, and Spain. It also publishes clinical research findings through its Journal du GORTEC and trial-specific newsletters.
Product overview
GORTEC (Groupe d'Oncologie Radiothérapie Tête Et Cou) is a French clinical research cooperative group specializing in head and neck oncology. Rather than a software product company, GORTEC coordinates and manages clinical trials as its primary activity. The organization offers clinical research coordination services, publishes scientific journals and trial-specific newsletters, and maintains a portfolio of ongoing clinical trials in radiotherapy and head and neck cancer treatment. Key offerings include the Journal du GORTEC publication and Clinical Trial Newsletters for studies such as ILLUMINE, ADCC, NIVOPOST-OP, and others.
Differentiator
Problem solved
Functional benefit
Products and services
- GORTEC Clinical Research Coordination Services Coordination and management of clinical studies in head and neck oncology, including radiotherapy research. The organization serves as a cooperative group (Groupe Coopérateur) that designs, initiates, and oversees multi-center clinical trials across France and international sites for oncology professionals, academic medical centers, and pharmaceutical partners.
- ILLUMINE Trial Phase III clinical trial in head and neck cancer sponsored by GORTEC in collaboration with Summit Therapeutics. Regulatory approvals obtained for activation in France, Belgium, and Spain.
- Ongoing Clinical Trials Portfolio Active Phase III clinical trials including ILLUMINE (2024-04) in head and neck cancer, IDEAL (2024-03), TATIANA (2024-01), AdCC (2023-01), and XXL (2022-01), spanning various stages of oncology research.
- Journal du GORTEC Periodical journal published by GORTEC covering clinical trial results, research discussions, and updates from the head and neck oncology field. Issues include Journal N°31 (October 2025) and Journal N°32 (April 2026).
Quantifiable outcome
- 63% disease-free survival at 3 years with nivolumab post-operative treatment in NIVOPOST-OP trial (+11% of patients cured with immunotherapy)
Companies that use GORTEC
Customer profileSegments2 records
Ideal customer profiles2 records
GORTEC technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
GORTEC partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core.
- Summit TherapeuticscoreGORTEC is sponsoring the ILLUMINE Phase III trial in head and neck cancer in collaboration with Summit Therapeutics. The trial has received regulatory approvals to start in France, Belgium, and Spain.
- AstraZenecacoreAstraZeneca is listed as an industrial partner of GORTEC. The partnership supports clinical trials in head and neck oncology conducted by the cooperative group.
- Bicara TherapeuticscoreBicara Therapeutics is listed as an industrial partner of GORTEC, supporting the group's clinical research activities in head and neck cancer.
- Leo PharmacoreLeo Pharma is listed as an industrial partner of GORTEC, contributing to the cooperative group's oncology research programs.
- Merck GroupcoreMerck Group is listed as an industrial partner of GORTEC, supporting clinical research activities.
- Merck MSDcoreMerck MSD (Merck Sharp & Dohme) is listed as an industrial partner of GORTEC for oncology clinical trials.
- NanobiotixcoreNanobiotix is listed as an industrial partner of GORTEC, contributing to head and neck cancer research programs.
- Intergroupe ORL (IGORL)coreGORTEC collaborates with IGORL (Intergroupe ORL - Head and Neck Intergroup) on joint professional meetings and research initiatives. The organizations hold combined annual meetings.
Scale indicators3 records
Recent moves7 records
Expansion highlights4 records
GORTEC competitors and assessment
Company assessmentBroad incumbents
- UNICANCER: UNICANCER is the French federation of Comprehensive Cancer Centers (CLCCs) and runs large-scale clinical research programs across all major tumor types. It is a broad incumbent peer to GORTEC within the French oncology research ecosystem, with overlapping investigator networks and sponsor relationships.
- ECOG-ACRIN Cancer Research Group: ECOG-ACRIN is a large US-based NCI-sponsored cooperative group conducting oncology clinical trials. Comparable to GORTEC as a multi-institutional academic cooperative group, though operating at substantially larger scale across all major tumor types.
Direct peers
- European Organisation for Research and Treatment of Cancer (EORTC) - re-listed for emphasis: Selected as a key peer representing the international cooperative oncology group tier that GORTEC competes against for cross-border trial mandates and pharma sponsorship in head and neck oncology.
- EORTC: EORTC is the leading European academic clinical research cooperative group in oncology. It is the most direct peer to GORTEC, conducting multi-center oncology trials across Europe with similar cooperative group governance and pharma-partnered funding model, though operating at significantly larger scale and broader therapeutic scope.
- NRG Oncology: NRG Oncology is a US-based cooperative group focused on radiation oncology and head and neck cancers. It is a direct peer to GORTEC in terms of radiation oncology and head and neck cancer trial focus, though operating across North America with NCI funding support.
- GERCOR: GERCOR is a French academic cooperative group conducting clinical trials in oncology with a similar multi-center, pharma-sponsored model. It is comparable to GORTEC as a national cooperative peer, though focused on different tumor types (mainly gastrointestinal and breast).
- FFCD (Fédération Francophone de Cancérologie Digestive): FFCD is a French cooperative group dedicated to digestive oncology clinical research. Comparable to GORTEC as a French national cooperative oncology group with similar governance and pharma-sponsored multi-center trial operations, though focused on GI cancers.
- TROG Cancer Research: TROG is the Trans-Tasman Radiation Oncology Group, an Australian/New Zealand cooperative group specializing in radiation oncology clinical trials. Directly comparable to GORTEC for its radiation oncology focus, multi-center trial model, and academic cooperative governance.
- IFCT (Intergroupe Francophone de Cancérologie Thoracique): IFCT is a French francophone cooperative group conducting clinical trials in thoracic oncology. It is directly comparable to GORTEC as a national French intergroup with the same cooperative governance, pharma-partnered trial model, and member-driven structure, though focused on lung cancer.
- ARCAGY-GINECO: ARCAGY-GINECO is a French cooperative group focused on gynecological oncology clinical research. Directly comparable to GORTEC as a French national cooperative group with similar member-driven governance and pharma-partnered trial operations.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
GORTEC social profiles
Digital presenceGORTEC financial estimates
Financial estimateRevenue estimate
Valuation estimate
GORTEC leadership team
Management profileNumber of profiles
Profiles2 records
GORTEC funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
GORTEC M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about GORTEC
What does GORTEC do?
GORTEC is a French academic cooperative group that coordinates and manages multi-center clinical trials and biological studies in head and neck oncology and radiation oncology. The organization designs, initiates, and oversees Phase III and translational research studies, collaborating with academic medical centers and pharmaceutical industrial partners across France, Belgium, and Spain. It also publishes clinical research findings through its Journal du GORTEC and trial-specific newsletters.
Is GORTEC a public or private company?
GORTEC is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was GORTEC founded?
GORTEC was founded in 1994. It employs 11 to 50 people.
Where is GORTEC based?
GORTEC is headquartered in Tours, France, in the Europe region.
Who are GORTEC's main competitors?
Broad incumbents on record are UNICANCER and ECOG-ACRIN Cancer Research Group. Direct peers are European Organisation for Research and Treatment of Cancer (EORTC) - re-listed for emphasis, EORTC, NRG Oncology, GERCOR, FFCD (Fédération Francophone de Cancérologie Digestive), TROG Cancer Research, IFCT (Intergroupe Francophone de Cancérologie Thoracique) and ARCAGY-GINECO.
Does GORTEC have an API?
No public API is recorded for GORTEC.
What industry is GORTEC in?
GORTEC's product category is Oncology Clinical Research Services. Its primary akta.pro industry code is HLAKAFAB, Medical Oncology, with a secondary code of HLAFAMAL, Clinical Research & Trial Central Laboratories. Its NAICS code is 54169 and its SIC code is 8731.